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Abstract
Background—Once-daily dosing of abacavir and lamivudine has been approved for adults, but
paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-
daily abacavir and lamivudine in children aged 3–<36 months.
Methods—Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks treatment with
twice-daily abacavir (8 mg/kg) with or without lamivudine (4 mg/kg) underwent plasma
pharmacokinetic sampling. Children then switched to once-daily abacavir (16 mg/kg) with or
without lamivudine (8 mg/kg), and sampling was repeated 4 weeks later. The area under the
plasma concentration–time curve over 24 h (AUC0–24) and the maximum concentration (Cmax)
were compared using geometric mean ratios (GMRs); 90% confidence intervals (CIs) within the
range of 0.80–1.25 were considered bioequivalent.
Results—A total of 18 children (4, 6 and 8 in the 3–<12, 12–<24 and 24–<36 month age ranges,
respectively) provided pharmacokinetic data for abacavir (17 for lamivudine). The GMR of
AUC0–24, once-daily versus twice-daily, was 1.07 (90% CI 0.92–1.23) for abacavir and 0.91 (90%
CI 0.79–1.06) for lamivudine. Cmax almost doubled on once-daily versus twice-daily dosing:
abacavir and lamivudine GMRs were 2.04 (90% CI 1.73–2.42) and 1.78 (90% CI 1.52–2.09),
respectively. At baseline, 12, 24 and 48 weeks, 89%, 94%, 100% and 89% of children had HIV-1
RNA<400 copies/ml, respectively.
Conclusions—Bioequivalence was demonstrated on AUC0–24 between twice-daily and once-
daily abacavir; very similar AUC0–24 values were seen for twice-daily and once-daily lamivudine.
Given that viral load suppression rates were maintained, these data suggest that once-daily
abacavir and lamivudine might be an option for children aged 3–<36 months.
Introduction
AIDS-related mortality and morbidity has decreased substantially since the introduction of
combination antiretroviral therapy (ART) in HIV-infected children [1,2]; however, long-
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term therapeutic success depends on good adherence [3–6]. Adherence is related to several
factors, including volume and palatability of medication, the complexity of medication
schedules and interference with daily activities [6–9]. In adults, once-daily medication has
been shown to enhance adherence and patient satisfaction with ART [10–13]. Good
adherence and acceptability to once-daily ART has also been reported in children [14].
Abacavir and lamivudine have been approved for once-daily dosing for adults [15,16].
PENTA 13, a pharmacokinetic (PK) study performed in HIV type-1 (HIV-1)-infected
children aged 2–13 years, showed that abacavir and lamivudine taken once-daily were well
tolerated and non-inferior in terms of PK profiles and continued HIV-1 RNA suppression,
compared with corresponding twice-daily regimens [17]. However, only three children
under 3 years of age were included. Very young children have a fluctuating gastrointestinal
absorption rate, a larger volume of distribution for water-soluble drugs and faster renal
clearance per kg body weight (the latter being the principal route of elimination for both
lamivudine and abacavir metabolites); therefore, it might not be appropriate to extrapolate
the findings of PENTA 13 to infants and younger children [16,18–20].
PENTA 15 (trial number ISRCTN38147516) was a multicentre, open-label, within-child,
crossover PK study in HIV-1-infected children aged 3–<36 months. The aim of the study
was to compare plasma PK parameters of once-daily versus twice-daily dosing of abacavir
and lamivudine. Secondary objectives were to describe age-related differences in once-daily
versus twice-daily PK parameters in three age groups (3–<12, 12–<24 and 24–<36 months),
and to describe child and family acceptability of (and adherence to) once-daily compared
with twice-daily dosage regimens.
Methods
Study population
HIV-1-infected children aged 3–<36 months taking twice-daily abacavir (Ziagen®;
GlaxoSmithKline, Research Triangle Park, NC, USA) with or without twice-daily
lamivudine (Epivir®; GlaxoSmithKline), both as oral solutions for at least 12 weeks as part
of combination ART, were included. HIV-1 RNA levels were required to be either <400
copies/ml or if ≥400 copies/ml to be stable or decreasing and <20,000 copies/ml, with no
plans to change medication in the next 12 weeks. Likewise, the percentage of CD4+ T-cells
was required to be stable or rising prior to entry. Children were excluded if they had an
intercurrent illness, were receiving concomitant therapy except prophylactic antibiotics or
had abnormal renal or liver function (grade ≥3). The protocol was approved by the ethics
committee for each participating centre. All parents/guardians provided written informed
consent.
Study design
At week 0, children on twice-daily abacavir 8 mg/kg (with or without twice-daily
lamivudine 4 mg/kg) had blood samples taken at 0 (pre-dose), 1, 2, 3, 4, 6, 8 and 12 h after
observed intake of medication. Children then switched to once-daily abacavir 16 mg/kg (and
once-daily lamivudine 8 mg/kg if applicable). The same total daily dose of both drugs was
given. Children took once-daily medication in the morning until the week 4 visit when a
second PK sampling (at 0 [pre-dose], 1, 2, 3, 4, 6, 8, 12 and 24 h) was performed. Children
were subsequently followed until week 48, with the intention for all to remain on once-daily
abacavir (with or without once-daily lamivudine) at least until week 12. Switch back to
twice-daily dosing was at the discretion of the physician and family. After week 4, once-
daily medication dosing could be changed from the morning to a different, but regular, time
Page 2
Antivir Ther. Author manuscript; available in PMC 2013 November 14.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
of day. Carers were asked to complete questionnaires on adherence to ART (week 0, 4 and
12) and on acceptability of once-daily dosing (week 0 and 12).
Pharmacokinetic analyses
Plasma concentrations of abacavir and lamivudine were determined by a validated HPLC
assay with ultraviolet detection at a wavelength of 260 nm; measurements were performed at
the Department of Pediatric Pharmacology and Pharmacogenetics (Clinical Investigation
Center CIC Inserm 9202, Hôpital Robert Debré, Paris, France). Methods were cross-
validated with the Department of Clinical Pharmacy of the Radboud University Nijmegen
Medical Center (Nijmegen, the Netherlands), where the assay was developed [21]. The
lower limit of quantification (LLQ) was 0.015 mg/l for both abacavir and lamivudine. PK
parameters (area under the plasma concentration–time curve [AUC0–T, h•mg/l], apparent
oral clearance relative to body weight [CL/F/kg, l/(h•kg)], maximum plasma concentration
[Cmax, mg/l]; minimum plasma concentration [Cmin, mg/l] and elimination half-life [t1/2, h])
were calculated using non-compartmental methods and the linear up/log down trapezoidal
procedure within WinNonlin version 5.2 (Pharsight Corporation; Mountain View, CA,
USA). The options ‘uniform weighting’ and ‘best-fit’ were used and concentrations below
LLQ were set to ‘0’ (when it appeared in the absorption phase) or ‘missing’ (when it
appeared in the elimination phase). For AUC0–T, T was 12 h for twice-daily and 24 h for
once-daily dosing. Daily AUC (AUC0–24) was estimated for the twice-daily regimen by
calculating AUC0–24=2×AUC0–T.
Sample size
Target enrolment was 18 children, 6 in each age group: 3–<12, 12–<24 and 24–<36 months.
If a child did not complete both PK evaluation days on twice-daily and once-daily regimens,
their data was not evaluable for the purposes of the study and an additional child in the
relevant age group was recruited as a replacement. On the basis of plasma abacavir PK data
from the PENTA 13 study [17], the standard deviation of change in log10(AUC0–24)
between twice-daily and once-daily dosing was approximately 0.13 log10 (h•mg/l). Eighteen
children providing plasma abacavir PK data on both twice-daily and once-daily regimens
was expected to provide at least 80% power for the width of the 90% confidence interval
(CI) for the mean log10(AUC0–24) difference between twice-daily and once-daily to be
<0.113. For example, the 90% CI for a ratio of geometric mean AUC0–24 of 1.00 (no
difference between twice-daily and once-daily AUC0–24 observed) would be 0.88–1.14.
Statistical analyses
Statistical calculations were performed using Stata version 10 (StataCorp LP, College
Station, TX, USA). For each child, ratios of AUC0–24, CL/F/kg and Cmax for once-daily
versus twice-daily were calculated. Overall geometric mean ratios (GMRs) were calculated
after log10 transformation of the within-patient ratios. For AUC0–24 and CL/F/kg, a GMR
with 90% CI including 1.00 and falling entirely within the range 0.80–1.25 was considered
bioequivalent. In each age group (3–<12, 12–<24 and 24–<36 months), geometric means
(GMs) were calculated separately for twice-daily and once-daily; GMRs were calculated for
once-daily versus twice-daily. Data were compared with published results from steady-state
PK studies in children using 8 mg/kg twice-daily or 16 mg/kg once-daily abacavir and 4 mg/
kg twice-daily or 8 mg/kg once-daily lamivudine (tablets and oral solution; PENTA 13
[17]); comparisons were also made with adults using 300 mg twice-daily or 600 mg once-
daily abacavir tablets (CAL102120 [22]) and 150 mg twice-daily or 300 mg once-daily
lamivudine tablets (EPV1001 [23]). Major resistance mutations were defined according to
the 2008 International AIDS Society–USA guidelines [24].
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Results
A total of 18 children, enrolled between July 2006 and May 2008, had two evaluable PK
days and were included in all main analyses (Figure 1). Safety and efficacy information on
five children who commenced once-daily therapy, but who had incomplete PK data, is given
separately (one switched back to twice-daily prior to the second PK day, two had lost
samples from one PK day, and two had incomplete sample collection [only 4 and 5 samples
were collected on the second PK day]). Six children were recruited but did not commence
once-daily therapy and were not followed: two did not attend their first PK day and four had
cannulation problems on their first PK day.
Baseline characteristics of the 18 vertically HIV-1-infected children (4, 6 and 8 children in
age groups 3–<12, 12–<24 and 24–<36 months, respectively) with two evaluable PK days
are given in Table 1. One child in the 24–<36 months age group was evaluated for abacavir
only (Table 1). Prior to the study, many children had been exposed to two ART classes (7
[39%] to nucleoside reverse transcriptase inhibitors [NRTIs] and protease inhibitors, and 9
[50%] to NRTIs and non-nucleoside reverse transcriptase inhibitors). Two (11%) children
had been exposed to all three classes. Sixteen (89%) children were taking all their ART
drugs twice-daily and the remaining two were taking a mixture of twice-daily and once-daily
medication (one taking emtricitabine once-daily and one taking nevirapine once-daily).
Pharmacokinetic analyses
One child, who had a missing 1 h sample on their first PK day, was excluded from the Cmax
analysis (Figure 1). One child missed their 24 h sample on the second PK day and was
excluded from Cmin analysis. Three children vomited post-dose on their second PK day. One
child (AUC0–24 abacavir 21.54, AUC0–24 lamivudine 7.35, CL/F/kg abacavir 0.72 and CL/
F/kg lamivudine 1.06) vomited approximately 50–100 ml at 20 min post-dose; all drugs
were given again and the PK analysis restarted. One child (AUC0–24 abacavir 11.20,
lamivudine 6.94; CL/F/kg abacavir 1.45 and lamivudine 1.10) had a very small vomit 20
min post-dose and drugs were not re-administered. One child (AUC0–24 abacavir 13.06,
lamivudine 5.76; CL/F/kg abacavir 1.23 and lamivudine 1.17) vomited approximately 10 ml
1 h post-dose and drugs were not readministered. All three children were included in all PK
analyses.
Abacavir pharmacokinetics
For the 18 children with evaluable abacavir PK data, median (interquartile range [IQR])
doses were 8.04 mg/kg (7.74–8.25) for twice-daily and 16.02 mg/kg (15.53–16.26) for once-
daily. Bioequivalence between twice-daily and once-daily dosing was demonstrated on
AUC0–24 (GMR once-daily versus twice-daily, 1.07 [90% CI 0.92–1.23]) and also for CL/F/
kg (Table 2 and Figure 2A). GMRs for AUC0–24 and CL/F/kg showed no linear trend with
age (P=0.6 for both). The GM of Cmax was approximately double on once-daily compared
with twice-daily dosing; there was no difference between age groups (P=0.3).
The GMs of AUC0–24, CL/F/kg and Cmax on twice-daily and once-daily dosing were
comparable with data obtained in children aged 2–13 years (PENTA 13 [17]; Table 2).
Slightly higher AUC0–24 and CL/F/kg were observed in children in both the PENTA 13 and
15 studies compared with adults [22].
Lamivudine pharmacokinetics
For the 17 children with evaluable lamivudine PK data, median (IQR) doses were 4.04 mg/
kg (3.87–4.13) for twice-daily and 8.02 mg/kg (7.77–8.13) for once-daily. Very similar
AUC0–24 values were seen for twice-daily and once-daily dosing of lamivudine (GMR once-
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daily versus twice-daily, 0.91 [90% CI 0.79–1.06]; Table 3 and Figure 2B), but higher than
expected variability resulted in the 90% CI falling slightly outside the bioequivalence
criteria. Similar results were observed for CL/F/kg. As for abacavir, the GM of Cmax was
approximately double on once-daily compared with twice-daily dosing. There were no
statistically significant differences among age groups for all PK parameters (P=0.2, P=0.3
and P=0.1 for AUC0–24, CL/F/kg and Cmax, respectively).
The GMs of AUC0–24, CL/F/kg and Cmax on twice-daily and once-daily dosing were
comparable with data obtained in children aged 2–13 years (PENTA 13 [17]; Table 3).
Additionally, AUC0–94 and Cmax were similar to adult data [23], although the CL/F/kg was
slightly higher in children.
Safety and efficacy
Eighteen children with two evaluable pharmacokinetic days—During the study,
no child changed ART regimen and no child discontinued once-daily abacavir (or once-daily
lamivudine if applicable) prior to week 12. One child switched back to twice-daily abacavir
and lamivudine at week 16, owing to adherence concerns and fluctuating HIV-1 RNA levels
(although at time of switching HIV-1 RNA was <50 copies/ml and subsequent results were
>50 copies/ml). Three children, all on zidovudine, abacavir, lamivudine and nevirapine at
baseline, discontinued zidovudine during the trial. Three children switched from twice-daily
to once-daily nevirapine (one subsequently switched back to twice-daily after therapeutic
monitoring) and two children switched to once-daily lopinavir/ritonavir. Overall, 5 (28%)
children experienced a period of taking all their ART medication once-daily during the
study.
Virological control was maintained throughout the study. At baseline, 4, 8, 12, 24 and 48
weeks, 89% (16/18), 93% (14/15), 93% (14/15), 94% (16/17), 100% (18/18) and 89%
(16/18) of children, respectively, had HIV-1 RNA<400 copies/ml. Moreover, the proportion
of children with HIV-1 RNA<50 copies/ml remained stable over time. The percentage of
CD4+ T-cells also remained stable. Of five children with HIV-1 RNA≥100 copies/ml at
screening, three had centralized resistance tests and no major mutations were detected (for
the other two children, one sample could not be amplified and one had no stored sample).
Six children had HIV-1 RNA≥100 copies/ml during the first 12 weeks of follow-up and
centralized resistance tests were performed on two (three could not be amplified and one had
no stored sample), detecting no major mutations.
Four hospitalizations were reported as serious adverse events (one croup, one scalp
laceration, one gastroenteritis, one diarrhoea and persistent vomiting [grade 2]); none were
judged to be related to ART. Two children had adverse events (one diarrhoea and vomiting
of medication [grade 2] and one febrile convulsion). No new CDC B and C events occurred
during the study and no child discontinued treatment because of adverse events.
Five children with incomplete pharmacokinetic data—Among five children with
incomplete PK data (Figure 1), three were followed until 48 weeks. All three remained on
once-daily abacavir and lamivudine and had HIV-1 RNA<400 copies/ml throughout. One
child was hospitalized to investigate vomiting and respiratory symptoms; tuberculosis was
excluded and vomiting judged probably related to nevirapine. The other two children had
limited follow-up data, but in both, vomiting was reported on once-daily abacavir and
lamivudine. The first child had severe nausea after commencing once-daily therapy and
switched back to twice-daily after 6 days. The second child was hospitalized at week 3 for
vomiting with increase of transaminases (aspartate aminotransferase 59 U/l and alanine
aminotransferase 46 U/l). This child remained on once-daily abacavir and lamivudine until
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their second PK assessment (PK data incomplete because of lost samples from first PK day),
but then immediately switched back to twice-daily.
Adherence and acceptability
At baseline, 4 and 12 weeks, 18/18, 18/18 and 16/18 carers, respectively, completed
questionnaires. Reported adherence since the last clinical visit on a visual analogue scale
ranged between 70% and 100%: 71% (week 0), 80% (week 4) and 69% (week 12) recorded
100% adherence. At week 0, one child missed a lamivudine dose the day before the PK
assessment day and another child missed one abacavir, lamivudine and lopinavir/ritonavir
dose 2 days before the PK assessment day. At weeks 4 and 12, no carers reported missed
doses over the previous 3 days.
At baseline, all carers thought switching from twice-daily to once-daily would make things
easier for them (15/18 [83%] a lot and 3/18 [17%] a little). This was supported after the
switch to once-daily abacavir/lamivudine, with all carers reporting that the switch had made
things easier for them (11/16 [69%] a lot and 5/16 [31%] a little). Overall, all carers (apart
from one who were unsure) preferred once-daily dosing and 14/16 (88%) preferred to give
the once-daily dose in the morning.
Discussion
In HIV-1-infected children aged 3–<36 months, bioequivalence was demonstrated on
AUC0–24 between twice-daily and once-daily dosing for abacavir; very similar AUC0–24
values were observed for lamivudine, although the 90% CI for the GMR fell slightly outside
the pre-set bioequivalence criteria. As expected, the observed Cmax was approximately 2×
higher on once-daily compared with twice-daily therapy for both drugs. Analysis of age-
related differences was limited by the small sample size per age group; however, no
consistent trend with age for AUC0–24, CL/F/kg or Cmax max was seen for either drug.
For abacavir, PK data in children aged 2–13 years (PENTA 13 [17]) were comparable with
data in this study. CL/F/kg was higher in children from both studies than in adults
(CAL102120 [22]). This might be explained by a difference in the relationship between CL/
F and weight, as CL/F has been reported to increase linearly with weight in children [25] but
exponentially (scaling 0.8) in adults [26]. This could lead to an apparent higher weight-
normalized CL/F in children compared with adults. Studies covering a larger age range are
required to further evaluate the effect of age and weight on clearance.
For lamivudine, age-dependent CL/F has been widely studied in children and a cutoff for
change at approximately 6 years has been reported [27]; lamivudine AUC was reported to be
similar in children aged >6 years receiving 8 mg/kg/day to adults receiving approximately 4
mg/kg/day (300 mg/day), but higher doses (>8 mg/kg/day) were required for children <6
years to achieve a comparable AUC. In our study, CL/F was comparable to that previously
reported (0.66 l/[h•kg]) in 59 children with a similar age range: 29 days to 3 years [28].
Further work on a larger dataset is needed to confirm these results because of high
variability; however, average AUC0–24 values for lamivudine in PENTA 15 were very
similar to those observed in the adult data [23].
We did not measure concentrations of the active intracellular triphosphates of abacavir and
lamivudine, as analysis is technically challenging and requires large volumes of blood.
Although the correlation between plasma concentration of an NRTI and its intracellular
triphosphate is imperfect, it is reasonable to assume that if plasma levels of the parent
compound are similar on once-daily and twice-daily dosing then, as in adults [22,23],
intracellular levels will also be similar.
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PENTA 15 was designed primarily as a single-arm crossover PK study and so strong
conclusions cannot be drawn about efficacy and safety of once-daily use of abacavir and
lamivudine. However, we observed no evidence of loss of efficacy over 48 weeks and there
were no major safety concerns. Of note, two children with incomplete PK data experienced
vomiting shortly after commencing once-daily abacavir and lamivudine, which caused them
to switch back to twice-daily. Large volumes of liquids might not be appropriate for all
infants.
Virological efficacy results in this study were similar to those observed in children aged 2–
13 years (PENTA 13 [17]); in PENTA 13, during 24 weeks of follow-up no child (n=20)
discontinued once-daily dosing and similar proportions had undetectable HIV-1 RNA at
baseline (16/20 [80%]) and 24 weeks (17/19 [89%]). In adults, a trial of 770 participants
[15] demonstrated that abacavir once-daily in combination with once-daily lamivudine and
efavirenz was non-inferior to abacavir twice-daily: at 48 weeks, 66% in the once-daily arm
compared with 68% in the twice-daily arm had undetectable HIV-1 RNA. For lamivudine, a
trial of 554 adults [16] demonstrated that lamivudine once-daily in combination with
zidovudine and efavirenz was equivalent to twice-daily dosing: at 48 weeks, 61% in the
once-daily arm compared with 59% in the twice-daily arm had undetectable HIV-1 RNA.
This has led to once-daily abacavir and lamivudine being a recommended dosing option for
these drugs in adults. Data from a substudy of the ARROW trial [29] on 24 Ugandan
children aged 3–12 years have recently reported similar AUC0–24 values for twice-daily and
once-daily abacavir and lamivudine. Further efficacy and safety data will be available from
a planned randomization of several hundred children to receive twice-daily or once-daily
dosing of abacavir and lamivudine within the ARROW trial.
Following the results from the CHER trial [30], guidelines recommend [31,32] infants start
ART as soon as possible after diagnosis; therefore, children infected vertically with HIV-1
are likely to face lifelong treatment. In this study, good adherence to ART was reported
throughout and all carers reported that daily dosing made life easier. Comments included, ‘it
makes it a lot easier if you’re leaving a child with someone else, for example, a
childminder’, ‘will not affect his sleeping any more’, ‘I will manage to work in the
morning’, ‘tranquillity in the evening’ and ‘easier to remember’. In PENTA 13 [14], 71% of
carers also reported that once-daily dosing of lamivudine/abacavir made things easier.
Although once-daily dosing might be ‘less forgiving’, if doses are missed this might be
offset by better long-term adherence and durability of ART with once-daily dosing, as is
now the goal for all therapy in adults.
In conclusion, PENTA 15 showed no major concerns with respect to the pharmacokinetics,
efficacy or safety of once-daily dosing of abacavir and lamivudine in children aged 3–<36
months. Data supports findings from the PENTA 13 trial and suggests that carers and
children, as well as adults, could benefit from the option of safe, effective and more
manageable daily ART regimens. However, at present, individual monitoring of children on
once-daily therapy is essential and once-daily versus twice-daily regimens of abacavir and
lamivudine should be further explored in large comparative efficacy and safety studies.
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Figure 1.
PENTA 15 participant flow
ABC, abacavir; Cmax, maximum plasma concentration; Cmin, minimum plasma
concentration; HIV-1, HIV type-1; PK, pharmacokinetic; 3TC, lamivudine; ±, with or
without.
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Figure 2.
Geometric mean plasma concentrations with 95% confidence intervals
Geometric means (95% confidence interval) of plasma concentrations of (A) abacavir and
(B) lamivudine.
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Table 1
Baseline characteristics
Characteristic Value
Evaluable children, n(%) 18 (100)
Median age, months (IQR) 23.4 (12.1–27.8)
Age range
 3–<12 months, n (%) 4 (22)
 12–<24 months, n (%) 6(33)
 24–<36 months, n (%) 8 (44)
Gender
 Male, n (%) 10(56)
 Female, n (%) 8 (44)
Median body weight, kg (IQR) 11.3 (10.3–13.0)
Ethnic origin
 White, n (%) 3 (17)
 Black, n (%) 14(78)
 Mixed, n (%) 1 (6)
CDC stage
 N, n (%) 7 (39)
 A, n (%) 3(17)
 B, n (%) 1 (6)
 C, n (%) 7 (39)
Median cumulative ART exposure, months (IQR) 11.3 (7.4–21.6)
Antiretroviral therapy combinationa
 3TC+ABC+NVP (±AZT or ±d4T), n (%) 10 (56)
 3TC+ABC+LPV/r (±AZT), n (%) 7 (39)
 FTC+ABC+LPV/r, n (%) 1 (6)
aAll children were taking all antiretroviral therapy (ART) drugs twice daily, with two exceptions: one child, who was on lamivudine (3TC) and
abacavir (ABC), was taking nevirapine (NVP) once daily; and one child on abacavir (ABC) and lopinavir/ritonavir (LPV/r) was taking
emtricitabine (FTC) once daily. The child evaluated for ABC only was 24–<36 months of age, female, 15.0 kg, White, CDC stage C and taking
FTC, ABC plus LPV/r. AZT, zidovudine; d4T, stavudine; IQR, interquartile range.
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Table 2
Abacavir pharmacokinetic parameters
PK parameter
Study
(subdivided by age
group)
Evaluable
patients, n
GM (95% CI)
twice-daily
GM (95% CI)
once-daily
GMR (90% CI)
once-daily versus
twice-daily
Reference
AUC0–24, h•mg/l PENTA 15 18 10.85 (8.89–13.24) 11.57 (9.89–13.53) 1.07 (0.92–1.23) –
 3–<12 months 4 12.68 (6.52–24.64) 15.90 (8.86–28.52) 1.25(1.12–1.41) –
 12–<24 months 6 13.89 (10.40–18.54) 10.60 (7.68–14.63) 0.76 (0.56–1.05) –
 24–<36 months 8 8.34 (6.27–11.08) 10.53 (8.87–12.50) 1.26 (1.07–1.48) –
PENTA 13 14 9.91 (8.26–11.89)a 13.37 (11.80–15.16)a 1.35 (1.19–1.54)  [17]
 2–6 years 9 9.27 (7.06–12.18)a 13.55 (11.19–16.42)a – –
 >6–13 years 5 11.17 (8.76–14.24)a 13.06 (10.91–15.63)a – –
CAL102120b 27 7.90 (6.66–9.39) 8.52 (7.23–10.04) 1.08(1.02–1.15)  [22]
CL/F/kg, l/h•kg PENTA 15 18 1.47 (1.21–1.79) 1.38 (1.17–1.62) 0.94 (0.81–1.08) –
 3–<12 months 4 1.23 (0.61–2.48) 0.97 (0.52–1.81) 0.79 (0.71–0.88) –
 12–<24 months 6 1.17 (0.94–1.46) 1.52 (1.11–2.09) 1.30 (0.97–1.76) –
 24–<36 months 8 1.91 (1.44–2.53) 1.52 (1.29–1.78) 0.79 (0.66–0.95) –
PENTA 13 14 1.58 (1.30–1.93)a 1.16(1.01–1.34)a 0.73 (0.64–0.84)  [17]
 2–6 years 9 1.80(1.37–2.36)a 1.21 (1.00–1.47)a – –
 >6–13 years 5 1.26 (0.96–1.64)a 1.08 (0.81–1.44)a – –
CAL102120b 27 1.09 (0.91–1.29) 1.01 (0.86–1.19) 0.93 (0.86–1.00)  [22]
Cmax, mg/l PENTA 15 1.38 (1.17–1.62) 4.68 (3.86–5.67) 2.04(1.73–2.42) –
 3–<12 months 4 2.43 (1.37–4.31) 5.89 (2.83–12.26) 2.42 (1.64–3.59) –
 12–<24 months 6 3.18 (2.24–4.52) 5.29 (3.70–7.56) 1.66 (1.12–2.46) –
 24–<36 months 7c 1.67 (1.10–2.53) 3.69 (2.95–4.61) 2.21 (1.74–2.80) –
PENTA 13 14 2.14(1.79–2.56)a 4.80 (4.04–5.71)a 2.25 (1.83–2.77)  [17]
 2–6 years 9 1.94(1.50–2.51)a 5.07 (3.92–6.56)a – –
 >6–13 years 5 2.54 (2.00–3.22)a 4.36 (3.39–5.60)a – –
CAL102120b 27 1.84(1.58–2.15) 3.85 (3.34–4.42) 2.09 (1.88–2.32)  [22]
Cmin, mg/l PENTA 15 17d 0.03 (<0.015–0.08)e <0.015(<0.015–0.07)e N/A –
T1/2, h PENTA 15 18 1.66 (0.99–2.95)e 2.15(l.40–4.98)e N/A –
a90% confidence interval (CI).
bAdult study.
cOne child excluded because of a missing 1 h plasma concentration on the first pharmacokinetic (PK) sampling day.
dOne child excluded because of a missing 24 h plasma concentration on the second PK sampling day.
eMedian (range). AUC0–24, daily area under the plasma concentration–time curve; CL/F/kg, apparent oral clearance relative to body weight;
Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; GM, geometric mean; GMR, geometric mean ratio; N/A, not
applicable; T1/2, elimination half-life.
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Table 3
Lamivudine pharmacokinetic parameters
PK parameter
Study
(subdivided by age
group)
Evaluable
patients, n
GM (95% CI)
twice-daily
GM (95% CI)
once-daily
GMR (90% CI)
once-daily versus
twice-daily
Reference
AUC0–24, h•mg/l PENTA 15 17 9.48 (7.89–11.40) 8.66 (7.46–10.06) 0.91 (0.79–1.06) –
 3–<12 months 4 9.24 (4.66–18.32) 10.31 (6.26–16.96) 1.11 (0.95–1.31) –
 12–<24 months 6 9.54 (6.71–13.57) 7.13 (5.84–8.71) 0.75 (0.58–0.96) –
 24–<36 months 7 9.58 (6.65–13.78) 9.27 (7.11–12.09) 0.97 (0.71–1.32) –
PENTA 13 19 8.88 (7.67–10.28)a 9.80 (8.64–11.12)a 1.12(1.03–1.21)  [17]
 2–6 years 10 7.60 (6.12–9.45)a 8.80 (7.43–10.43)a – –
 >6–13 years 9 10.55 (8.82–12.63)a 11.04 (9.06–3.45)a – –
EPV1001b 60 9.21 (8.81–9.63) 8.70 (8.28–9.14) 0.94 (0.92–0.97)  [23]
CL/F/kg.l/h•kg PENTA 15 17 0.79 (0.65–0.96) 0.86 (0.74–1.01) 1.10(0.95–1.28) –
 3–<12 months 4 0.79 (0.36–1.73) 0.72 (0.42–1.26) 0.92 (0.73–1.16) –
 12–<24 months 6 0.80 (0.55–1.18) 1.05 (0.88–1.25) 1.31 (1.00–1.71) –
 24–<36 months 7 0.77 (0.53–1.12) 0.81 (0.61–1.07) 1.05 (0.77–1.43) –
PENTA 13 19 0.90 (0.78–1.04)a 0.80 (0.70–0.92)a 0.89 (0.82–0.96)  [17]
 2–6 years 10 1.09 (0.89–1.34)a 0.92 (0.78–1.08)a – –
 >6–13 years 9 0.73 (0.63–0.85)a 0.69 (0.55–0.87)a – –
EPV1001b 60 0.44 (0.42–0.47) 0.47 (0.44–0.50) 1.06 (1.02– 1.10)  [23]
Cmax, mg/l PENTA 15 16c 1.05 (0.88–1.26) 1.87 (1.65–2.13) 1.78 (1.52–2.09) –
 3–<12 months 4 1.04 (0.76–1.41) 2.37 (1.57–3.57) 2.29 (1.73–3.01) –
 12–<24 months 6 1.22 (0.82–1.80) 1.71 (1.46–2.02) 1.41 (1.14–1.74) –
 24–<36 months 6c 0.92 (0.62–1.35) 1.75 (1.39–2.20) 1.91 (1.35–2.69) –
PENTA 13 19 1.11 (0.96–1.29)a 2.09 (1.80–2.42)a 1.90 (1.67–2.16)  [17]
 2–6 years 10 0.94 (0.78–1.13)a 1.72 (1.48–1.99)a – –
 >6–13 years 9 1.34(1.08–1.67)a 2.59 (2.04–3.28)a – –
EPV1001b 60 1.19 (1.12–1.26) 1.97 (1.84–2.11) 1.66 (1.57–1.74)  [23]
Cmin, mg/l PENTA 15 16d 0.08 (0.03–0.27)e 0.05 (<0.015–0.21)e N/A –
T1/2, h PENTA 15 17 2.99 (2.38– 4.54)e 5.35 (2.83–13.23)e N/A –
a90% confidence interval (CI).
bAdult study.
cOne child excluded because of a missing 1 h plasma concentration on the first pharmacokinetic (PK) sampling day.
dOne child excluded because of a missing 24 h plasma concentration on the second PK day.
e
Median (range). AUC0–24, daily area under the plasma concentration–time curve; CL/F/kg, apparent oral clearance relative to body weight;
Cmax, maximum plasma concentration; Cmin, minimum plasma concentration; GM, geometric mean; GMR, geometric mean ratio; N/A, not
applicable; T1/2, elimination half-life.
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